326030.KO Sk Biopharmaceuticals Co Ltd

Healthcare Biotechnology Korea Stock Exchange
90,600 KRW
Close of Nov 5, 2026
67,800 144,100
Market cap
KRW 7.10T
P/E
15.8x
P/B
6.08x
ROE
37.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 326030.KO undervalued?

Graham number
Price90,600
Graham value43,907
Premium106.3%

326030.KO trades 106.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sk Biopharmaceuticals Co Ltd fundamental analysis

No fundamental analysis for Sk Biopharmaceuticals Co Ltd yet.

Sk Biopharmaceuticals Co Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sk Biopharmaceuticals Co Ltd

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SK…

Full company profile